CHICAGO—Avanafil may enable men with mild to severe erectile dysfunction (ED) to engage successfully in sexual intercourse within 15 minutes after dosing, new findings show.
John P. Mulhall, MD, of Memorial Sloan-Kettering Cancer Center in New York, and colleagues studied 597 men with mild to severe ED: 85 with diabetes, 391 without diabetes, and 121 who underwent bilateral nerve-sparing radical prostatectomy (RP). On a per-attempt basis, 59.7% of diabetic and non-diabetic patients and 36.4% of post-RP patients experienced one or more successful intercourse attempts in 15 or minutes or less after avanafil dosing, compared with 27.6% and 4.5%, respectively, among placebo recipients, according to findings presented at the World Meeting on Sexual Medicine.
The meeting is co-sponsored by the International Society for Sexual Medicine and the Sexual Medicine Society of North America.
Avanafil, which is a phosphodiesterase type 5 inhibitor, was approved for treating ED on April 27. It is marketed by Vivus Inc. under the trademark name Stendra.